Supriya Lifesciences

Supriya Lifesciences achieves milestone with ANVISA GMP Certification

This article delves into Supriya Lifesciences’ recent success in obtaining GMP certification from ANVISA Brazil, marking a significant stride in the company’s commitment to quality and future growth.

In a major achievement, Supriya Lifesciences Limited proudly announced that its manufacturing site in Lote Parshuram has been awarded the Good Manufacturing Practice (GMP) certification by Brazil’s Regulatory Authority, ANVISA.
The Chairman and Managing Director proudly announced that the Lote Factory successfully cleared the rigorous GMP inspection, earning a flawless “Zero” Observation for Compliance. This accomplishment not only highlights Supriya’s unwavering commitment to the highest quality standards but also showcases the excellence of its smart manufacturing practices.

The successful audit has broader implications, as it marks the registration of 8 Active Pharmaceutical Ingredients (APIs) with CADIFA, setting the stage for expedited registration of the company’s remaining APIs. This achievement positions Supriya Lifescience Ltd. for increased market presence in the Brazilian Pharmaceutical market, as the certification from ANVISA is widely recognised for its stringent requirements.

About Supriya Lifescience Ltd
Established in 1987, Supriya Lifescience Ltd. has emerged as a global leader in the manufacturing of pharmaceutical ingredients. The company’s state-of-the-art facility in Khed, District Ratnagiri, is certified by prominent regulatory bodies, including USFDA, EUGMP, and Health Canada. With a robust Research and Development (R&D) division, active Drug Master Files (DMFs) and Certificate of Suitability (CEP) filings, Supriya Lifescience Ltd. operates worldwide with compliance to regulatory standards such as EMA, US FDA, WHO and now ANVISA.

The company’s core business ethos revolves around ethical values and Environmental, Health, and Safety (EHS) standards, focusing on the development of APIs and Intermediates for both innovators and generic companies, along with exclusive partnerships as a Contract Development and Manufacturing Organization (CDMO).

The recent success in passing Brazil’s stringent GMP inspection not only affirms Supriya’s commitment to excellence but also facilitates the registration of 8 APIs with CADIFA. This accomplishment acts as a catalyst, enabling smoother and faster registrations for the company’s remaining APIs and positioning Supriya Lifescience Ltd. for broader market penetration.

Future Outlook
Two New R&D Centres: Supriya Lifescience Ltd places a strong emphasis on Research and Development (R&D) for future growth. The recently commissioned R&D lab at Lote Parshuram, spanning 800 sqm, focuses on new product development and Contract Development and Manufacturing Organization (CDMO) opportunities. Another lab in Ambernath, set to be operational by Q3FY24, will further contribute to the company’s expansion plans.

New Markets: With a current presence in over 86 countries and business relations with 1200+ customers, Supriya Lifescience Ltd. is strategically expanding its footprint. The company’s sales and regulatory teams are actively engaging in registering products, sending samples, and supplying APIs to qualify Supriya as a reliable source in the pharmaceutical market. Special attention is given to the North American market, Japan, Australia, and New Zealand for targeted business expansion.

Recognizing its expertise in large-scale special chemical manufacturing, Supriya Lifescience Ltd. is venturing into the Contract Manufacturing Organization (CMO) and CDMO space. Recent collaborations, such as the exclusive API supplier agreement with a leading European company, position the company as a key player in the industry.

Capacity Enhancement:
To meet the growing demand and seize emerging opportunities, Supriya Lifescience Ltd. is actively enhancing its manufacturing capabilities. The ongoing projects include the development of a new manufacturing block (E block) at Lote Parshuram, set to be operational by Q3FY24, and the establishment of a new manufacturing block with a capacity of 70 KL at Ambernath. These initiatives will boost the total capacity from 597 KL to 900 KL by Q3 FY24.

Supriya Lifesciences Limited’s recent GMP certification from ANVISA stands as a testament to its unwavering commitment to quality and adherence to international standards. As the company forges ahead with ambitious R&D initiatives, explores new markets, expands its presence in the CMO/CDMO space, and enhances its manufacturing capacities, it positions itself as a formidable player in the global pharmaceutical landscape. The successful inspection in Brazil not only opens doors to the Brazilian pharmaceutical market but also reinforces Supriya Lifesciences Ltd.'s standing as a reliable and innovative pharmaceutical solutions provider.

Disclaimer: This post has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.